Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Rheumatic heart disease usually accompanied by weakened immune function. And the
cardiopulmonary bypass further aggravating the decline of immune function. Therefore, the
prevention of Postoperative immune function collapse is of great clinical value, and
immunomodulatory therapy with thymosin alpha
1 may be beneficial. This study was designed to test the hypothesis that the administration
of thymosin alpha 1 will Improve the immune function and prognosis of patients.